Bayer AGXSWX:BAYN 35 EV-to-EBIT is -15,707.20 as of Jul. 08, 2026. GuruFocus rates XSWX:BAYN with a GF Score™ of 35/100 and a GF Value™ of CHF24.67 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 690 Drug Manufacturers companies, Bayer AG ranks worse than 99.42% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bayer AG's Enterprise Value is CHF72,473 Mil.
Bayer AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-5 Mil. Therefore, Bayer AG's EV-to-EBIT for today is -15,707.20.
The historical rank and industry rank for Bayer AG's EV-to-EBIT or its related term are showing as below:
XSWX:BAYN'
s EV-to-EBIT Range Over the Past 10 Years
Min: -151.62 Med: 10.99 Max: 1001.68
Current: 970.87
During the past 13 years, the highest EV-to-EBIT of Bayer AG was 1001.68. The lowest was -151.62. And the median was 10.99.
XSWX:BAYN's EV-to-EBIT is ranked worse than 99.42% of 690
companies
in the Drug Manufacturers industry
Industry Median: 15.91
vs XSWX:BAYN: 970.87
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bayer AG's Enterprise Value for the quarter that ended in Mar. 2026 was CHF28,990 Mil.
Bayer AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG EV-to-EBIT Related Terms
Bayer AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bayer AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BAYN vs LLY, JNJ, ABBV: EV-to-EBIT Comparison
For the Drug Manufacturers - General subindustry, Bayer AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bayer AG's EV-to-EBIT falls into.
Bayer AG's current Enterprise Value is CHF72,473 Mil.
Bayer AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG (XSWX:BAYN) has a EV-to-EBIT of -15,707.20 as of Jul. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bayer AG and its competitors. According to the industry distribution chart, Bayer AG ranks #686 out of 690 companies in the Drug Manufacturers industry, placing it in the top 99.4%.
Is Bayer AG's EV-to-EBIT too high?
Bayer AG's current EV-to-EBIT is -15,707.20. Based on the distribution chart, Bayer AG ranks #686 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bayer AG has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #686 out of 690 companies for EV-to-EBIT. This places Bayer AG in the lower half of its industry. The industry median EV-to-EBIT is 15.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.91, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bayer AG and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current EV-to-EBIT is -15,707.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.67, compared to a current price of CHF48.57 — trading 96.9% above its estimated fair value. The current EV-to-EBIT is -15,707.20. Bayer AG's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current EV-to-EBIT is -15,707.20 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF48.57 is trading 96.9% above its estimated GF Value™ of CHF24.67.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
EV-to-EBIT: -15,707.20
GF Value™: CHF24.67 vs. price of CHF48.57 (96.9% above fair value)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
35GF Score
Get the complete analysis for XSWX:BAYN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 
